The Fibromyalgia Treatment Market will be worth US$ 1.2 Bn at a CAGR of 6.9% between 2021-2031. With seamless digital exploration on the anvil, greater patient volume is likely to be enclosed worldwide with no geographical barriers to hold back. Telehealth is there is added to the digital transformation wave, thereby revolutionizing the healthcare vertical.
A strong product pipeline and increasing occurrence of fibromyalgia are the major factors that are projected to boost demand for fibromyalgia treatment over the coming years. Fibromyalgia is characterized by musculoskeletal pain along with anxiety, depression, headaches, irritable bowel syndrome, memory and mood issues, sleep disorders, and fatigue. It is accepted that fibromyalgia modifies the pain sensation mechanism controlled by the brain.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/32455
As indicated by the National Institute of Health (NIH), around 1.5 billion individuals experienced chronic pain in 2016. Unhealthy lifestyles, sub-optimal diets, and undesirable lack of physical exercise are broadly increasing the danger of chronic pain. Different factors such as rising instances of rheumatic diseases, unmet medical needs, growing awareness among the population, rising geriatric population, and increasing popularity of Chinese therapy options are driving the development of the market.
Key players are concentrating on research & development activities to present new products in the market and provide more treatment options. Launch and approval of new fibromyalgia treatment drugs are anticipated to aid market expansion in the future.
The global fibromyalgia treatment market is estimated to be valued at US$ 1.2 Bn in 2021 and is expected to exhibit a CAGR of around 7% over the forecast period (2021 – 2031).
Key Take aways from Market Study
- Under products, anticonvulsants hold the highest value in the market, as they help provide relief from pain and treat the same for a long term.
- By distribution channel, hospital pharmacies hold a notable revenue share of around 46%.
- North America accounted for a share of over 40% in 2020 to become the most lucrative among all regions, and is expected to show significant growth over the next ten years.
- Europe is the next dominating region with a market share of 20% in 2020, due to well-developed medical infrastructure largely supported by governments in the region.
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/32455
“Increasing burden of chronic pain, risingincidence of traumatic stress and road accidents, growing awareness among the population, and increasing research & development activities are all expected to drive market growth,” says a Persistence Market Research analyst.
Collaborations and Acquisitions – Imperative Strategy for Market Players
Major companies are actively engaging in acquisitions and expansion in order to enhance their product portfolios and outreach to a large number of customers. Globally, leading companies, in order to maintain their market position, follow the trend of acquiring companies who are facing a large number of product recalls.
- In May 2020, AbbVie acquired Allergan plc, which helped the company broaden its existing portfolio and strengthen its presence in the global biopharmaceutical sector.
- In October 2020, FDS BioSciences, Inc. acquired a U.S.-based company, Prismic Pharmaceuticals, which is engaged in developing novel therapies for fibromyalgia treatment.
Access Full Report @ https://www.persistencemarketresearch.com/checkout/32455
What else is in the report?
Persistence Market Research offers a unique perspective and actionable insights on the fibromyalgia treatment market in its latest study, presenting historical demand assessment of 2016-2020 and projections for 2021-2031, based on the product (anti-depressants, anticonvulsants, muscle relaxants, and analgesics) and distribution channel (hospital pharmacies, retail pharmacies, drug stores, and online sales), across seven key regions of the world.
Access Related Reports:
Treatment for Syndromes of Dementia and Movement Disorders Market:
The global treatment for syndromes of dementia and movement disorders market was valued at USD 12,859.8 million in 2014 and is expected to grow at a CAGR of 8.6% from 2014 to 2020, to reach an estimated value of USD 21,154.8 million in 2020.
Sickle Cell Disease Treatment Market:
Global sickle cell disease treatment market is expected to witness robust growth during the forecast period. This growth is expected to be primarily driven by increasing adoption of therapies, growing awareness regarding the sickle cell disease treatment in MEA region.
Wearable Injector Market:
Persistence Market Research analysts present an in-depth study on the global wearable injector market, highlighting the key revenue drivers, market inhibitors, growth trends, and lucrative opportunities that are prevalent in the global market for wearable injector during a projected period of eight years from 2018 to 2026.
MRI Systems Market:
With continuous technology advancements, rising preference for non-invasive diagnosis, and increasing incidence of neurological disorders, the global MRI systems market will witness 2X growth by market value over the forecast period of 2019 to 2029.
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com